FDLI Panel Discusses Ways FDA Can Weather Recent Drug Safety Controversy
This article was originally published in The Gray Sheet
Executive Summary
An effort by drug and device marketers to tone down direct-to-consumer advertising could help FDA avoid structural changes threatened by congressional critics, communications expert Wayne Pines suggested